



TERMINATION OF FORWORX ASSET PURCHASE AGREEMENT

VANCOUVER, BC, CANADA – September 21, 2020 – Cabbay Holdings Corp. (Cabbay or the “Company”) is pleased to announce that the Asset Purchase Agreement with ForwoRx Therapeutics Inc. has terminated and the assets have been returned to Cabbay’s 100% owned subsidiary Alta-Sun Samson Holdings Corp. (“Alta-Sun”)

The agreement with ForwoRx Therapeutics Inc. included PTL-202 of a treatment for fibrosis and a sublingual formulation of sildenafil citrate for erectile dysfunction and pulmonary arterial hypertension.

To date PTL-202 a candidate for treatment of fibrosis specifically Idiopathic Pulmonary Fibrosis has completed phase 1 clinical and preclinical studies. In the clinical study the interaction of the drugs in the combination showed a positive interaction that will result in patients requiring smaller doses of PTL-202. The preclinical studies demonstrated that the combination of the drugs in PTL-202 was more effective than the individual components at reducing inflammation and fibrosis in the animal studies. Given big pharma’s interest in the fibrosis space and earlier stage therapies, Alta-Sun may seek out a strategic partner for the continued development and commercialization of PTL-202.

The next step in the development of PTL-202 is the initiation of a phase 1b dose ranging study in humans.

Included in the returned assets is the intellectual property for the development and to commercialize worldwide a new formulation of sildenafil citrate for erectile dysfunction. This reformulation, PTL-2015, of an existing drug may reduce the side effects and speed the onset associated with current formulations of sildenafil. Alta-Sun may seek out a commercialization partner in Europe for PTL-2015.

Erectile Dysfunction

Erectile Dysfunction (ED) is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Working from the most conservative projections the British Journal of Urology expects the number of men with erectile dysfunction (ED) to more than double from 152 million in 1995 to 322 million by 2025. The PTL-2015 Oral Disintegrating Tablet (ODT) formulation to treat ED, is a premium product for consumers that is fast-acting, with the potential to reduce common side effects. The ODT product for Erectile Dysfunction is designed to meet consumer demand and fill a niche not serviced by big pharma and generics, as 70% of patients prefer drugs in an ODT form.

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is characterized by scar tissue building up in the air sacs of the lungs, slowly suffocating the patient. Once diagnosed, the average life expectancy is 2.8 years. There is no cure for this disease. IPF kills more people annually than either breast cancer or prostate cancer. Decision Resources Group estimates the market size for IPF therapies in Europe and the United States at \$4.6 billion by 2020.

For further information, please contact:

Douglas H. Unwin,
President & CEO
(604) 762-5355
Doug.unwin@telus.net

FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Readers should not place undue reliance on the Company’s forward-looking statements, as the Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company’s business, or if the Company’s estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.